Department of Industrial Pharmacy, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, Giza, Egypt.
Department of Pharmaceutics, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, Giza, Egypt.
Int J Nanomedicine. 2020 Jun 11;15:4079-4090. doi: 10.2147/IJN.S250960. eCollection 2020.
The aim of this study is to develop efficient localized therapy of sertaconazole nitrate for the treatment of vaginal candidiasis.
Sertaconazole nitrate-loaded cationic liposomes were prepared by thin-film hydration method and coated with different concentrations of pectin (0.05%, 0.1% and 0.2%) to develop mucoadhesive liposomes. The formulated mucoadhesive vesicles were characterized in terms of morphology, entrapment efficiency, particle size, zeta value, mucoadhesive properties and drug release. The selected formula was incorporated into a gel base and further characterized by an ex vivo permeation study in comparison with conventional sertaconazole gel. Also, the in vivo study was performed to assess the efficacy of sertaconazole mucoadhesive liposomal gel in treating rats with vaginal candidiasis.
The mucoadhesive liposomes were spherical. Coating liposomes with pectin results in increased entrapment efficiency and particle size compared with uncoated vesicles. On the contrary, zeta values were reduced upon coating liposomes with pectin indicating efficient coating of liposomes with pectin. Mucoadhesive liposomes showed a more prolonged and sustained drug release compared with uncoated liposomes. Ex vivo study results showed that mucoadhesive liposomal gel increased sertaconazole tissue retention and reduced drug tissue penetration. In the invivo study, the mucoadhesive liposomal gel showed a significant reduction in the microbial count with a subsequent reduction in inflammatory responses with the lowest histopathological change compared with conventional gel.
The study confirmed the potentiality of employing mucoadhesive liposomes as a successful carrier for the vaginal delivery of antifungal drugs.
本研究旨在开发硝酸舍他康唑的有效局部治疗方法,用于治疗阴道念珠菌病。
采用薄膜水化法制备硝酸舍他康唑载阳离子脂质体,并采用不同浓度的果胶(0.05%、0.1%和 0.2%)进行包衣,以开发具有黏膜黏附性的脂质体。对所制备的黏膜黏附性囊泡进行形态学、包封率、粒径、Zeta 值、黏膜黏附性和药物释放等方面的评价。选择的配方被纳入凝胶基质中,并与常规的硝酸舍他康唑凝胶进行体外渗透研究进行进一步的特征描述。此外,还进行了体内研究,以评估硝酸舍他康唑黏膜黏附性脂质体凝胶治疗阴道念珠菌病大鼠的疗效。
黏膜黏附性脂质体呈球形。与未包衣的囊泡相比,用果胶包衣脂质体可提高包封率和粒径。相反,用果胶包衣脂质体后 Zeta 值降低,表明果胶对脂质体进行了有效的包衣。黏膜黏附性脂质体与未包衣脂质体相比,具有更持久和持续的药物释放。体外研究结果表明,黏膜黏附性脂质体凝胶增加了硝酸舍他康唑在组织中的保留,并减少了药物在组织中的渗透。在体内研究中,与常规凝胶相比,黏膜黏附性脂质体凝胶显著降低了微生物计数,随后降低了炎症反应,组织病理学变化最小。
该研究证实了黏膜黏附性脂质体作为阴道递药的有效载体的潜力。